Japanese journal of clinical oncology最新文献

{"title":"Update on the management of BCOR::CCNB3 sarcoma.","authors":"Jungo Imanishi, Kenji Sato, Yoshinao Kikuchi, Asako Yamamoto, Shiori Watabe, Taisuke Matsuyama, Chiaki Sato, Hiroshi Kobayashi, Hirotaka Kawano","doi":"10.1093/jjco/hyaf111","DOIUrl":"10.1093/jjco/hyaf111","url":null,"abstract":"<p><p>BCOR::CCNB3 sarcoma is a rare sarcoma defined by the BCOR::CCNB3 fusion gene. It predominantly affects males under 20, with a slight predominance of bone origin. Initially grouped as 'Ewing-like,' it is now a distinct entity, a major part of 'sarcoma with BCOR genetic alterations.' Incidence is low, estimated at under 10 annual cases in Japan. Radiologically, it can mimic other high-grade sarcomas, with variable lytic or sclerotic bone lesions and nonspecific soft tissue findings. By contrast, it sometimes appears well-defined and benign-like. Pathologically, the detection of BCOR::CCNB3 fusion is key to diagnosis. Histology varies from small round cells to spindle cells, showing CD99, BCOR, Cyclin D1, and SATB2 positivity, with CCNB3 differentiating it from BCOR-ITD. Molecular testing confirms the diagnosis. Treatment involves wide resection and chemotherapy, with the Ewing sarcoma protocol often chosen. Approximately 20% are metastatic at diagnosis, and local recurrence after surgery occurs in as high as ⁓20% of BCOR::CCNB3 sarcomas. The relatively high local recurrence rate is probably because of the infiltrative growth. Complete response to neoadjuvant chemotherapy may indicate a better prognosis. Less frequent metastasis at diagnosis indicates that this sarcoma is less aggressive than Ewing sarcoma. Five-year overall survival is ⁓75%, but the prognosis of non-resectable or metastatic cases is worse. Further research is crucial for tailored treatment. Due to the tumor's super-rarity, collaborative, multi-institutional studies are essential, allowing for robust clinical trials and outcome analyses. Long-term follow-up studies are also necessary to assess late effects and survival.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1097-1104"},"PeriodicalIF":2.2,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144626310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of tumor necrosis on comprehensive genomic profiling success in pancreatic cancer: a retrospective study.","authors":"Takuya Doi, Hirotoshi Ishiwatari, Nobuyuki Ohike, Junya Sato, Hiroki Sakamoto, Masahiro Yamamura, Tomoko Norose, Yuko Kakuda, Yoichi Yamamoto, Masao Yoshida, Noboru Kawata, Kazunori Takada, Sayo Ito, Kenichiro Imai, Kinichi Hotta, Hiroyuki Ono","doi":"10.1093/jjco/hyaf156","DOIUrl":"https://doi.org/10.1093/jjco/hyaf156","url":null,"abstract":"<p><strong>Objectives: </strong>Pancreatic cancer frequently presents with tumor necrosis, which may influence the success of comprehensive genomic profiling in endoscopic ultrasound-guided tissue acquisition specimens. This study aimed to evaluate the relationship between tumor necrosis and comprehensive genomic profiling success.</p><p><strong>Methods: </strong>This single-center retrospective study enrolled patients diagnosed with pancreatic cancer via endoscopic ultrasound-guided tissue acquisition, whose tissue samples were submitted for FoundationOne® CDx analysis between November 2019 and November 2023. Based on the FoundationOne® CDx report, a 'passed' result indicated successful analysis. Histological type, tumor quantity, and necrosis were evaluated as pathological factors. Univariable and multivariable analyses were conducted to identify factors associated with successful FoundationOne® CDx.</p><p><strong>Results: </strong>Among 109 patients included in this study, the overall success rate of FoundationOne® CDx analysis was 67.9%. Extensive tumor necrosis (>50%) was significantly associated with a lower success rate of FoundationOne CDx analysis (28.6% [>50%] vs. 70.6% [≤50%], P = 0.034). Among the 83 cases that met the quantity criteria for FoundationOne® CDx analysis, the success rate was significantly lower in cases with extensive necrosis (>50%) than in those with limited necrosis (40% [2/5] vs. 83% [65/78]; P = 0.036). Multivariate analysis identified extensive necrosis (odds ratio [OR] 0.09, P = 0.015), samples that met the quantity criteria for FoundationOne® CDx analysis (OR 14.90, P < 0.0001), and pancreatic ductal adenocarcinoma histology (OR 4.21, P = 0.038) as significant factors influencing the success of FoundationOne® CDx analysis.</p><p><strong>Conclusions: </strong>Extensive tumor necrosis observed on pathological examination is associated with a lower success rate of FoundationOne® CDx analysis in pancreatic cancer.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145238625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Protocol summary of a randomized controlled phase III trial for confirming the superiority of local radiotherapy for prostate cancer patients with high-volume metastasis sensitive to hormonal therapy: the JCOG2011 (HimeRT study).","authors":"Naoki Terada, Keiji Nihei, Rihito Aizawa, Shintaro Narita, Takahiro Kojima, Masaki Shiota, Shusuke Akamatsu, Takahiro Kimura, Takahiro Inoue, Mikio Sugimoto, Yuta Sekino, Keita Sasaki, Taro Shibata, Haruhiko Fukuda, Hiroyuki Nishiyama, Hiroshi Kitamura, Takashi Mizowaki","doi":"10.1093/jjco/hyaf157","DOIUrl":"https://doi.org/10.1093/jjco/hyaf157","url":null,"abstract":"<p><p>Local therapy is not considered a standard treatment option for patients with high-volume metastatic prostate cancer. Our research group's previous retrospective study indicated potential benefits of local radiotherapy (LRT) for some high-volume metastatic prostate cancer patients, but prospective studies have yet to confirm these findings. We have thus planned a multicenter, open-label, randomized controlled phase III trial to confirm the efficacy of adding LRT to systemic hormonal therapy with androgen deprivation therapy plus an androgen receptor pathway inhibitor in a population of high-volume metastatic prostate cancer patients for whom the hormonal therapy is effective for 6 months. The primary endpoint is failure-free survival, defined as the time from randomization to prostate-specific antigen progression, radiological progression, clinical progression, or death from any cause. We aim to enroll 360 patients from 56 institutions over a 4-year period. This trial is registered at the Japan Registry of Clinical Trials (study no. jRCT1031220676).</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145238660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Practical guidance on the clinical management of ocular adverse events associated with belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Recommendations from a Japanese expert panel.","authors":"Kazutaka Sunami, Tomoaki Fujisaki, Toshinari Funaki, Michiko Ichii, Shigeki Ito, Morio Matsumoto, Koh-Ichi Oshima, Kazuhito Suzuki, Teruhito Takakuwa","doi":"10.1093/jjco/hyaf148","DOIUrl":"https://doi.org/10.1093/jjco/hyaf148","url":null,"abstract":"<p><strong>Background: </strong>Multiple myeloma is a significant cause of mortality, and treatments for patients with relapsed/refractory multiple myeloma have limited efficacy. Treatment regimens with belantamab mafodotin have demonstrated significant improvement in progression-free survival compared with current standard-of-care regimens but have been associated with an increased risk of ocular adverse events (OAEs). These practice guidelines aim to provide recommendations to support Japanese clinicians in managing OAEs and facilitate confidence in the use of belantamab mafodotin.</p><p><strong>Methods: </strong>An expert panel of Japanese haematologists/oncologists and ophthalmologists convened to discuss and agree on the recommendations for managing OAEs in patients treated with belantamab mafodotin.</p><p><strong>Results: </strong>The expert panel identified four key themes and 13 clinical questions to guide the recommendations for managing belantamab mafodotin-related OAEs in the real-world setting in Japan. The four key themes were: (i) identification of OAEs associated with belantamab mafodotin treatment; (ii) management and dose modification of belantamab mafodotin treatment for OAEs; (iii) multidisciplinary collaboration for effective management of ocular events; and (iv) a patient-centred approach to the management of OAEs.</p><p><strong>Conclusions: </strong>The recommendations in these practice guidelines build on published clinical trial evidence and the practical experience of the expert panel to help Japanese clinicians make informed treatment decisions in the management of multiple myeloma in the real-world setting.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145238680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Health-related quality of life changes in nasopharyngeal cancer patients: a propensity score-matched comparison of intensity-modulated proton therapy and volumetric-modulated arc therapy.","authors":"Po-Jui Chen, Ching-Rong Lin, Sheng-Ping Hung, Ching-Hsin Lee, Po-Hung Chang, Shiang-Fu Huang, Chung-Jan Kang, Tuan-Jen Fang, Li-Ang Lee, Pei-Wen Wu, Kuang-Hsu Lien, Joseph Tung-Chieh Chang","doi":"10.1093/jjco/hyaf115","DOIUrl":"https://doi.org/10.1093/jjco/hyaf115","url":null,"abstract":"<p><strong>Background: </strong>Despite the dosimetric advantages of intensity-modulated proton therapy (IMPT) in treating patients with nasopharyngeal carcinoma (NPC), it remains unclear whether these advantages confer improved health-related quality of life (HRQoL) compared to state-of-the-art photon-based techniques such as volumetric-modulated arc therapy (VMAT).</p><p><strong>Patients and methods: </strong>Patients with NPC eligible for definitive radiation therapy (RT) were invited to participate in the longitudinal observational study. Patient-reported outcomes were assessed using the Functional Assessment of Cancer Therapy-Head & Neck Cancer (FACT-HN) questionnaire at multiple time points: before, during, and after treatment. Propensity score matching (PSM) was utilized to align the IMPT group with the VMAT group. Longitudinal changes in HRQoL were then analyzed using generalized estimating equations (GEEs).</p><p><strong>Results: </strong>From 2008 to 2021, a total of 353 patients were enrolled in the study. After applying PSM at a 1:3 ratio, the final analysis included 213 patients in the VMAT group and 71 patients in the IMPT group. There were no significant differences were noted in the mean changes of FACT-HN scores from baseline between the IMPT and VMAT groups during treatment or throughout the follow-up periods as follows (IMPT vs. VMAT): -13.3 vs -14.4 (during RT), 2.2 vs. 1.0 (3 months post-RT), 5.4 vs. 8.5 (6 months post-RT), 10.8 vs. 10.1 (12 months post-RT), 10.2 vs. 10.5 (24 months post-RT), and 13.2 vs. 11.1 (36 months post-RT). Among all the subscales, only the emotional well-being (EWB) subscale demonstrated a significant difference at 36 months, favoring IMPT with scores of 2.7 versus 1.8 (p = 0.026). No significant differences were detected at other time points or within other subscales of interest.</p><p><strong>Conclusions: </strong>This study found no clinically significant differences in overall HRQoL, as measured by the FACT-HN questionnaire, between IMPT and VMAT in the treatment of NPC.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145238673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety profiles of dasatinib in pediatric patients: a real-world pharmacovigilance assessment based on the FAERS database.","authors":"Yuanyuan Yang, Weihao Ma, Hongbo Fu, Yanqiong Zhou, Yan Lin","doi":"10.1093/jjco/hyaf154","DOIUrl":"https://doi.org/10.1093/jjco/hyaf154","url":null,"abstract":"<p><strong>Objective: </strong>Dasatinib was approved for treating pediatric patients with philadelphia chromosome-positive chronic myeloid leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. While its efficacy has been proven, comprehensive safety data in pediatric populations remain limited. This study utilizes data from the food and drug administration adverse event reporting system (FAERS) to evaluate and characterize adverse events (AEs) reported in pediatric patients treated with dasatinib.</p><p><strong>Methods: </strong>Data from the FAERS between 2014 Q1 and 2024 Q4 were analyzed. Disproportionality analysis was performed to identify AEs reported in pediatric patients treated with dasatinib.</p><p><strong>Results: </strong>A total of 382 pediatric cases involving dasatinib were reported. The most frequent system organ classes included general disorders and administration site conditions, injury, poisoning, and procedural complications, and gastrointestinal disorders. Notably, previously unreported AEs such as hemorrhagic enterocolitis, lymphoid tissue hyperplasia, hydrocephalus, and hemorrhagic cystitis were identified, raising potential new safety concerns. Additionally, instances of off-label use were observed, particularly in regions where dasatinib is not recommended for pediatric patients, underscoring the importance of vigilant AEs monitoring to ensure patient safety.</p><p><strong>Conclusion: </strong>This study highlights the need for enhanced pharmacovigilance and proactive monitoring in pediatric patients receiving dasatinib to ensure treatment safety and improve clinical outcomes, and provides supporting evidence for the safe use of dasatinib in pediatric populations.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145212357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of starting dose of tyrosine kinase inhibitors on outcomes following combination therapy of immune checkpoint inhibitors with tyrosine kinase inhibitors for previously untreated advanced renal cell carcinoma.","authors":"Hiroki Ishihara, Koichi Nishimura, Yuki Nemoto, Shinsuke Mizoguchi, Takayuki Nakayama, Hironori Fukuda, Hiroaki Shimmura, Yasunobu Hashimoto, Kazuhiko Yoshida, Junpei Iizuka, Tsunenori Kondo, Toshio Takagi","doi":"10.1093/jjco/hyaf152","DOIUrl":"https://doi.org/10.1093/jjco/hyaf152","url":null,"abstract":"<p><strong>Background: </strong>The impact of the starting dose of tyrosine kinase inhibitors (TKIs) following combination therapy of immune checkpoint inhibitors with TKIs (i.e. IO-TKI) for advanced renal cell carcinoma (RCC) remains unclear.</p><p><strong>Methods: </strong>We retrospectively evaluated clinical data from 155 patients treated with first-line IO-TKI for RCC. Patients were categorized into full-dose and reduced-dose groups based on their starting dose of TKIs. Effectiveness and safety profiles were compared between groups.</p><p><strong>Results: </strong>A reduced starting dose was administered to 52 patients (34%). These patients were older (P = 0.0137) and received pembrolizumab plus axitinib more frequently, while lenvatinib plus pembrolizumab was less used (P = 0.0258) compared to the full-dose group. Progression-free survival and overall survival did not significantly differ between the full-dose and reduced-dose groups (P = 0.202 and P = 0.309, respectively). Although the objective response rate appeared higher in the full-dose group, the difference was not statistically significant after adjusting for other covariates (P = 0.0588). Safety profiles were comparable, with no significant differences in TKI dose reduction, drug interruption or discontinuation, or glucocorticoids use (P > 0.05). However, adverse events of grade ≥3 were more frequent in the full-dose group, although not statistically significant (P = 0.121).</p><p><strong>Conclusion: </strong>The starting dose of TKIs did not significantly impact clinical outcomes following IO-TKI for RCC. These findings suggest a potential for the optimization of the starting dose of TKIs; however, prospective studies are warranted to confirm these findings.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145191758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Author's reply to \"A questionnaire-based cross-sectional study on neuropathic pain in patients with cancer in Japan: a deeper look into potential confounding variables\".","authors":"Saori Hashiguchi","doi":"10.1093/jjco/hyaf151","DOIUrl":"https://doi.org/10.1093/jjco/hyaf151","url":null,"abstract":"","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145175447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A questionnaire-based cross-sectional study on neuropathic pain in patients with cancer in Japan: a deeper look into potential confounding variables.","authors":"Memuna Jehan Zeb","doi":"10.1093/jjco/hyaf150","DOIUrl":"https://doi.org/10.1093/jjco/hyaf150","url":null,"abstract":"","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145130917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment outcomes of definitive radiotherapy for unresectable salivary gland cancers: a multicenter, retrospective study in northern Japan.","authors":"Akira Ohkoshi, Ryo Ishii, Kenjiro Higashi, Tomonori Kambayshi, Satoshi Kano, Takahiro Kusaka, Daisuke Matsushita, Kosuke Murayama, Yuya Miyakura, Satoshi Kubota, Ryosuke Sato, Shino Godo, Hiroki Tomizawa, Satoshi Toyoma, Ai Tagawa, Akina Shirotori, Yukio Katori","doi":"10.1093/jjco/hyaf147","DOIUrl":"https://doi.org/10.1093/jjco/hyaf147","url":null,"abstract":"<p><strong>Background: </strong>Treatment of unresectable salivary gland cancers is challenging. This multicenter, retrospective study aimed to evaluate the treatment outcomes of definitive radiotherapy, with or without chemotherapy, for locally advanced, unresectable, salivary gland cancers.</p><p><strong>Methods: </strong>A total of 27 patients with unresectable salivary gland cancers who underwent concurrent chemoradiotherapy or radiotherapy with curative intent between 2012 and 2022 at 13 hospitals in northern Japan were included in this study. Overall survival (OS) and progression-free survival (PFS) were assessed, and factors affecting OS and PFS were identified through univariate and multivariate Cox regression analyses. The variables evaluated included age, sex, primary site, histological type, clinical T and N status, clinical stage, treatment type, and radiation type.</p><p><strong>Results: </strong>Seven patients received concurrent chemoradiotherapy, and 20 patients received radiotherapy (6 photon, 11 proton, 3 heavy ion). With a median follow-up period of 28 months, the three-year OS and PFS rates for the 27 patients were 54.4% and 27.8%, respectively. Patients who received concurrent chemoradiotherapy had better PFS than those who received radiotherapy alone (HR 0.16, 95% CI 0.03-0.81, P = .026).</p><p><strong>Conclusions: </strong>Definitive radiotherapy for locally advanced, unresectable, salivary gland cancers resulted in relatively good outcomes. Concurrent chemoradiotherapy was associated with better PFS than radiotherapy.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145112967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}